Indian Pharma Companies Show Exceptional Performance in the U.S.

Bangalore: The performance of the Indian pharma companies might not seem very pleasant at the moment, but their U.S. businesses are acting as a life saver. During the months of July and Aug, the Indian pharma companies have witnessed a slow growth of 15-20 percent. However, the next few quarters are expected to show a growth of 20-25 percent. The performance in September quarter is expected to be impressive due to depreciation in rupee, which in turn will boost gains from realizations from the U.S. businesses, reports Kiran Kabtta Somvanshi of Economic Times.

The domestic pharma industry has experienced a slow growth during the last few quarters due to the ambiguous drug pricing policy and the retailers’ agitation that took place in Maharashtra. Pharma companies like Lupin, Dr. Reddy’s Labs and Cadila Healthcare exhibited an unimpressive performance along with GSK Pharma, Novartis and Pfizer.

Also Read:
10 Fascinating Facts about the Indian Economy
Fall of India's Biggest Wealth Creators